Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 11/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719326 | 0.88 | GCG (0.46) | GCGGLP1RGCGRGIPRSMN1; SMN2 | |
| SCHEMBL719280 | 0.80 | GCGR (0.42) | GCGGLP1RGCGRGIPRSMN1; SMN2 | |
| SCHEMBL719002 | 0.79 | RCE1 (0.52) | RCE1HDAC6CMA1MTNR1A | |
| SCHEMBL718994 | 0.74 | RCE1 (0.38) | GCGRCE1HDAC6 | |
| SCHEMBL718203 | 0.72 | GCGR (0.45) | GCGGCGRSMN1; SMN2TP53 | |
| SCHEMBL721583 | 0.72 | GCG (0.42) | GCGGLP1RGCGRGIPRHDAC6 | |
| SCHEMBL719331 | 0.71 | GCGR (0.53) | GCGGLP1RGCGRGIPRSMN1; SMN2 | |
| SCHEMBL720571 | 0.71 | GCGR (0.53) | GCGGLP1RGCGRGIPRSMN1; SMN2 | |
| SCHEMBL718289 | 0.70 | GCGR (0.44) | GCGGLP1RGCGRGIPRSMN1; SMN2 | |
| SCHEMBL718349 | 0.70 | GCG (0.44) | GCGGLP1RGCGRGIPRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GLP1R 5/4885GCGR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.